Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kumar Budur

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
The Lancet. Neurology|November 19, 2022
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trialMichael J Soileau, Jason Aldred, Kumar Budur, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
Measuring cognition and function in the preclinical stage of Alzheimer's diseaseSandra Weintraub, Maria C Carrillo, Sarah Tomaszewski Farias, et al.
Neurology and Therapy|August 26, 2023
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 StudyJason Aldred, Eric Freire-Alvarez, Alexander V Amelin, et al.
Neurology and Therapy|October 10, 2023
Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 StudyJason Aldred, Eric Freire-Alvarez, Alexander V Amelin, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
The Lancet. Neurology|November 19, 2022
Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trialMichael J Soileau, Jason Aldred, Kumar Budur, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 30, 2018
Measuring cognition and function in the preclinical stage of Alzheimer's diseaseSandra Weintraub, Maria C Carrillo, Sarah Tomaszewski Farias, et al.
Neurology and Therapy|August 26, 2023
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 StudyJason Aldred, Eric Freire-Alvarez, Alexander V Amelin, et al.
Neurology and Therapy|October 10, 2023
Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson's Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 StudyJason Aldred, Eric Freire-Alvarez, Alexander V Amelin, et al.
Pageof 4